Fluorometholone Acetate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

Fluorometholone Acetate is a corticosteroid with excellent anti-inflammatory action against inciting agents of mechanical, chemical, or immunological nature. Fluorometholone is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. In clinical studies on patients' eyes treated with both Dexamethasone and Fluorometholone suspensions, Fluorometholone demonstrated a lower propensity to increase intraocular pressure than did Dexamethasone.

The bottle should be shaken before use. Instill 1 to 2 drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosage may be safely increased to 2 drops every hour. Care should be taken not to discontinue therapy prematurely.

Use in Children: Safety and effectiveness have not been demonstrated in children under 2 years of age.

Specific drug interaction studies have not been conducted with Fluorometholone ophthalmic suspension.

Fluorometholone Acetate ophthalmic suspension is contraindicated in patients with acute superficial Herpes simplex keratitis, fungal diseases of ocular structures, vaccinia, varicella, mycobacterial infection of the eye, most other viral diseases of the cornea and conjunctiva, tuberculosis of the eye, or hypersensitivity to the constituents of this medication.

Elevation of intraocular pressure with possible development of glaucoma, loss of visual acuity or defects in fields of vision, eye irritation, ocular hyperaemia, eye pain, visual disturbance, foreign body sensation, eyelid edema, blurred vision, eye discharge, eye pruritus, eye swelling, posterior subcapsular cataract formation, ulcerative keratitis, ocular infection (including bacterial, fungal and viral), punctate keratitis, hypersensitivity, rash and delayed wound healing.

Pregnancy Category B3. Fluorometholone ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether ophthalmic use of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

Steroid medication in the treatment of patients with a history of Herpes simplex keratitis requires great caution. Eye drops containing a corticosteroid should not be used for more than 10 days except under strict supervision with regular checks for intraocular pressure. Corticosteroids may mask, activate or aggravate an infection of the eye. If no improvement is seen after a few days of application, another form of treatment should be used.

Ophthalmic Steroid preparations

Store in a dry place and away from light. Keep out of reach of children. To prevent contamination of the dropper tip and suspension, care should be taken not to touch the eyelids, surrounding areas, fingers or other surfaces with the dropper tip of the bottle. The bottle should be tightly closed when not in use. Do not use after 4 weeks of first opening.